NeuroSearch A/S

NEUR 
(NasdaqOMXC) 
 

To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed.

dkk 3.72 <%= Resources.Global.txtUp %>
Updated 08:00:02
Change % 0.27% Stock price increasing
Change 0.01 Stock price increasing
Volume 2,149
High DKK 3.72
Low DKK 3.72
Open DKK 3.72
ISIN DK0010224666
Prev close DKK 3.71
# of shares 24.55M
Market cap 91.34M DKK
Intraday

NeuroSearch A/S
Market is open (until 16:00) - Delayed 15 min
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  3.72 6.9% Stock price increasing 7.5% Stock price increasing 14.8% Stock price increasing 38.8% Stock price increasing 59.7% Stock price increasing
Key Figures (m DKK)
Turnover
EBIT
Net Profit
Equity
Balance
2015
0
-6,488
-5,538
72,400
78,594
2014
0
-13
-8
78
84
2013
29
-10
12
88
92
2012
121
-290
-276
81
208
2011
0
-383
-678
321
841
2010
69
-328
-259
994
1,392
2009
85
-356
-287
1,174
0
2008
67
-366
-382
0
0
2007
115
-253
-268
1,121
0
Powered by TradingView

Related

Latest 1 week 1 month 3 months 6 months 1 year
YTD
 
Competitors Open
 
Orexigen Therapeutics Inc 4.24 -13.1% Stock price decreasing 32.1% Stock price increasing 82.0% Stock price increasing -3.9% Stock price decreasing 142.3% Stock price increasing 143.7% Stock price increasing
 
Vivus Inc 1.10 0.0% Stock price unchanged -7.6% Stock price decreasing -9.8% Stock price decreasing 3.8% Stock price increasing 4.8% Stock price increasing -4.3% Stock price decreasing
 
Arena Pharmaceuticals Inc 1.45 -5.8% Stock price decreasing 5.8% Stock price increasing -4.0% Stock price decreasing -13.7% Stock price decreasing -10.5% Stock price decreasing 2.1% Stock price increasing
 
H Lundbeck A/S 293.00 1.5% Stock price increasing 0.0% Stock price unchanged 11.3% Stock price increasing 6.2% Stock price increasing 17.3% Stock price increasing 2.0% Stock price increasing

Company profile

NeuroSearch is a biopharmaceutical company specializing in central nervous diseases (CNS). The company has two businesses: Specialty Pharma, focusing on completing the development and marketing of their first product; Huntexil against Huntington's disease. The second business NsDiscovery, manages early drug discoveries. The drug Tesofensine against obesity is also ready for clinical phase III and NeuroSearch seeks a partner for completion of development. Main risk factor for drug development is financial risk. The company has several drug discovery- and development collaborations with major pharmaceutical companies such as Abbott, Eli Lilly and Janssen Pharmaceuticals. The cooperation entitles NeuroSearch to premarketing milestone payments on each compound developed and potentially royalties if the drug is commercialized.

Peers

Instruments Last Change  
Orexigen The.. 4.24 0.0% Stock price unchanged
100,36,36,24,30,36,12,21,60,36
Vivus Inc 1.10 0.0% Stock price unchanged
20,80,60,100,60,100,100,100,100,60
Arena Pharma.. 1.45 0.0% Stock price unchanged
100,100,78,71,71,28,28,21,35,0
Lundbeck A/S 293.00 0.0% Stock price decreasing
0,11,100,55,11,33,33,33,33,0

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 February 2017 08:21:03
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170217.2 - EUROWEB3 - 2017-02-22 09:21:03 - 2017-02-22 08:21:03 - 1000 - Website: OKAY